['hypertrophic cardiomyopathy']
['eleclazine', 'placebo']

        Key Inclusion Criteria:

          -  Established diagnosis of hypertrophic cardiomyopathy defined by standard criteria as a
             maximal left ventricular wall thickness ≥ 15 mm at initial diagnosis

          -  Exertional symptoms including at least one of the following:

               -  New York Heart Association (NYHA) Class ≥ II dyspnea

               -  Canadian Cardiovascular Society (CCS) Class ≥ II angina

          -  Screening (baseline) peak VO2 < 80% of predicted for age, sex, and weight

          -  Ability to perform an upright treadmill cardiopulmonary exercise test (CPET)

        Key Exclusion Criteria:

          -  Known aortic valve stenosis (moderate or severe)

          -  Known coronary artery disease

          -  Left ventricular systolic dysfunction (ejection fraction < 50%)

          -  Recent septal reduction procedure (ie, surgical myectomy or alcohol septal ablation)
             within six months prior to screening or such a procedure scheduled to occur during the
             study

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      